Merck's respiratory syncytial virus prevention monoclonal antibody antiviral drug Anfuchar has been approved in China.

On June 15, Merck announced that its long-acting monoclonal antibody, Clerovivant monoclonal antibody injection, has recently been approved by the China National Medical Products Administration for the prevention of lower respiratory tract infections caused by RSV in neonates and infants who are about to enter or born in the first respiratory syncytial virus (RSV) season.